soul trial oral semaglutide cardiovascular outcomes results 2024 nejm (NEJM 2025): led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in serious AEs. #Semaglutide #CardioDiabetes #updatesinmedicine FLOWing with the SemagluTIDE —

The role of the vagus nerve in appetite control: implications for the pathogenesis of obesity

The administration says Medicare will begin covering certain GLP-1 drugs, commonly used for diabetes and weight loss, starting July 1, with out-of-pocket costs dropping to around $50 per month

The posttranslational regulation of APE/Ref-1 activities seems to reside into two non-mutually exclusive mechanisms, i.e

3fh) and was able to lessen the glucose-lowering effect of linagliptin in both PDX1Cre control and Gcg RA PDX1Cre mice

Both forms are used exclusively in research settings and are not interchangeable without consideration of experimental design